| Prev Close | 0.52 |
| Open | 0.49 |
| Day Low/High | 0.46 / 0.50 |
| 52 Wk Low/High | 0.44 / 4.75 |
| Volume | 1.89M |
VIVUS, Inc. (VVUS)
0.47
0.05
10.29
OTC
| Exchange | OTC |
| Shares Outstanding | 17.87B |
| Market Cap | 10.84M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
4 Stocks That Are Fit for Fitness
These companies should feast as more obese Americans turn to exercise and healthy foods.
Looking at What Didn't Work
Time to examine a couple that didn't pan out.
Companies Ripe for Activism
Hedge fund manager Gregory Taxin of Clinton Group talks about when companies hit a critical point that makes them ripe for activism.
2 Ways to Play Vivus
The short-term picture has changed.
Viva La Vivus?
This looks ready to make a move higher.
Beware of 'Earnings Torpedos'
Some of the market's favorite stocks have entered a danger zone.
Playing Obesity Drugs the ETF Way
Liquidity is key, and one ETF stands above the rest.
Obesity Treatment Shift Could Aid Stocks
Obesity costs are a pain point, which often create good investments.
The 5 Dumbest Things on Wall Street: March 1
Here is this week's roundup of the dumbest actions on Wall Street.
The Next Big Thing in Biotech
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Cramer: ADP Report is Irrelevant
Jim Cramer says we should throw out the ADP report and the BLS should out source the work to TIBCO.
Weight Loss Pills Not a Threat, Says Medifast CEO
Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.
The Next Big Thing in Biotech: Obesity Drugs
Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.
The Next Big Thing in Biotech: FDA Approvals
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
The Next Big Thing in Biotech: Vivus
Adam Feuerstein, senior columnist for TheStreet, says Vivus is the next big thing in biotech.
Don't Chase ARNA
The stock is way too extended to consider buying at current levels.
Biotechs Get Interesting
The sector has been attracting the hot money for a couple weeks.
Slow, but Positive
The longer this action persists, the more anxious folks will be to put idle cash to work.